Soichi Hirai

发表

Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients

K. Takayama, J. Uchino, Tadaaki Yamada, 2020, Scientific Reports.

Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer

Tadaaki Yamada, K. Takayama, J. Uchino, 2019, Journal of clinical medicine.

Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors: A Multicenter Observational Study in Japan

K. Takayama, Y. Hasegawa, J. Uchino, 2022, Journal of Thoracic Oncology.

Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer

K. Takayama, J. Uchino, Tadaaki Yamada, 2019, Cancer medicine.

Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer

Young Hak Kim, M. Horinaka, T. Sakai, 2023, npj Precision Oncology.

Effective combined therapy with ramucirumab for advanced pulmonary pleomorphic carcinoma

K. Takayama, Tadaaki Yamada, Y. Kaneko, 2018, Respirology Case Reports.

Comparison of the prognosis of symptomatic cerebral infarction and pulmonary embolism in patients with advanced non‐small cell lung cancer

Young Hak Kim, K. Takayama, Tadaaki Yamada, 2023, Cancer Medicine.

Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101)

M. Endo, A. Notsu, T. Tokito, 2024, Targeted oncology.

AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells.

K. Kunimasa, Shinsaku Tokuda, K. Morimoto, 2024, Cancer letters.

The Significance of Longitudinal Psoas Muscle Loss in Predicting the Maintenance Efficacy of Durvalumab Treatment Following Concurrent Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer: A Retrospective Study

Y. Chihara, Yusuke Kunimatsu, A. Yoshimura, 2024, Cancers.